These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 25192879)

  • 41. Clinical outcomes of carbon ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix in phase 1/2 clinical trial (protocol 9704).
    Wakatsuki M; Kato S; Ohno T; Karasawa K; Kiyohara H; Tamaki T; Ando K; Tsujii H; Nakano T; Kamada T; Shozu M;
    Cancer; 2014 Jun; 120(11):1663-9. PubMed ID: 24591084
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy.
    Du XL; Tao J; Sheng XG; Lu CH; Yu H; Wang C; Song QQ; Li QS; Pan CX
    Gynecol Oncol; 2012 Apr; 125(1):151-7. PubMed ID: 22198339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer.
    Folkert MR; Shih KK; Abu-Rustum NR; Jewell E; Kollmeier MA; Makker V; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Feb; 128(2):288-93. PubMed ID: 23159818
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of nodal recurrences of endometrial cancer with IMRT.
    Ho JC; Allen PK; Jhingran A; Westin SN; Lu KH; Eifel PJ; Klopp AH
    Gynecol Oncol; 2015 Oct; 139(1):40-6. PubMed ID: 26193429
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The normal tissue sparing obtained with simultaneous treatment of pelvic lymph nodes and bladder using intensity-modulated radiotherapy.
    Søndergaard J; Høyer M; Petersen JB; Wright P; Grau C; Muren LP
    Acta Oncol; 2009; 48(2):238-44. PubMed ID: 18759144
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
    De S; Kannan V; Deshpande S; Anand V; Ghadi Y
    J Cancer Res Ther; 2010; 6(1):58-64. PubMed ID: 20479549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O; Zelefsky MJ; Shippy A; Chan H; Fuks Z; Yamada Y; Hunt M; Greenstein S; Amols H
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):330-7. PubMed ID: 18164858
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients.
    Schwarz JK; Wahab S; Grigsby PW
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):1258-63. PubMed ID: 20932657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preoperative intensity modulated radiation therapy and chemotherapy for locally advanced vulvar carcinoma: analysis of pattern of relapse.
    Beriwal S; Shukla G; Shinde A; Heron DE; Kelley JL; Edwards RP; Sukumvanich P; Richards S; Olawaiye AB; Krivak TC
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1269-74. PubMed ID: 23273997
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute and late toxicity in prostate cancer patients treated by dose escalated intensity modulated radiation therapy and organ tracking.
    Ghadjar P; Vock J; Vetterli D; Manser P; Bigler R; Tille J; Madlung A; Behrensmeier F; Mini R; Aebersold DM
    Radiat Oncol; 2008 Oct; 3():35. PubMed ID: 18937833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer.
    Al-Mamgani A; van Rooij P; Verduijn GM; Mehilal R; Kerrebijn JD; Levendag PC
    Laryngoscope; 2013 Feb; 123(2):386-93. PubMed ID: 23404489
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Extended field intensity modulated radiation therapy for gynecologic cancers: Is the risk of duodenal toxicity high?
    Xu KM; Rajagopalan MS; Kim H; Beriwal S
    Pract Radiat Oncol; 2015; 5(4):e291-7. PubMed ID: 25532491
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical trial of prophylactic extended-field carbon-ion radiotherapy for locally advanced uterine cervical cancer (protocol 0508).
    Wakatsuki M; Kato S; Kiyohara H; Ohno T; Karasawa K; Tamaki T; Ando K; Tsujii H; Nakano T; Kamada T; Shozu M;
    PLoS One; 2015; 10(5):e0127587. PubMed ID: 25993047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant volumetric-modulated arc therapy with simultaneous integrated boost in endometrial cancer. Planning and toxicity comparison.
    Macchia G; Cilla S; Morganti AG; Deodato F; Legge F; Piermattei A; Chiantera V; Scambia G; Valentini V; Ferrandina G
    Acta Oncol; 2014 Feb; 53(2):251-8. PubMed ID: 24050516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Simultaneous Integrated Boost (SIB) Versus Sequential Boost in Anal Cancer Patients: A Single-Center Experience.
    Khosla D; Kapoor R; Dey T; Kataria V; Singh R; Kumar D; Oinam AS; Gupta R; Rana SS; Shah J; Singh H; Irrinki S; Madan R
    J Gastrointest Cancer; 2024 Jun; 55(2):759-767. PubMed ID: 38236375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intensity-modulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study.
    Rochet N; Sterzing F; Jensen AD; Dinkel J; Herfarth KK; Schubert K; Eichbaum MH; Schneeweiss A; Sohn C; Debus J; Harms W
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1382-9. PubMed ID: 19628341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IMRT with simultaneous integrated boost and concurrent chemotherapy for nasopharyngeal cancer: plan evaluation and treatment outcome.
    Kim JW; Cho JH; Keum KC; Kim JH; Kim GE; Lee JY; Kim SK; Lee CG
    Jpn J Clin Oncol; 2012 Dec; 42(12):1152-60. PubMed ID: 23077243
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering Cancer Center experience.
    de Arruda FF; Puri DR; Zhung J; Narayana A; Wolden S; Hunt M; Stambuk H; Pfister D; Kraus D; Shaha A; Shah J; Lee NY
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):363-73. PubMed ID: 15925451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.